Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene ...

Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...

The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

Vaccine manufacturer Bharat Biotech International Limited (BBIL) is making a foray into the cell and gene therapy (CGT) space ...

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily ...

Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.